Stryker shares tumble despite strong Q2 results and raised guidance
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a global pharmaceutical firm, has announced a second-quarter dividend of $1.50 per share on its outstanding common stock. Shareholders on record as of the close of business on May 16, 2025, will be eligible for the dividend, which is scheduled for payment on June 10, 2025. According to InvestingPro data, Lilly has maintained dividend payments for 55 consecutive years, with a current dividend yield of 0.73% and impressive 15.4% dividend growth over the last twelve months.
This declaration continues the company’s long-standing practice of returning value to its shareholders through periodic dividend payments. Eli Lilly has a history of nearly 150 years in the pharmaceutical industry, focusing on addressing significant health challenges worldwide. The company’s research spans various therapeutic areas, including diabetes care, obesity treatment, Alzheimer’s disease, immune system disorders, and cancer. With a robust financial health score rated as "Good" by InvestingPro, Lilly demonstrates strong market performance with a 12.8% total return over the past year and maintains a solid gross profit margin of 81.7%.
While the dividend payment reflects Eli Lilly’s current financial strategies and shareholder commitment, the company’s press release includes a cautionary statement. It underscores the inherent risks and uncertainties in pharmaceutical research and development that could affect future results. The company advises that actual outcomes may vary due to multiple factors and directs interested parties to its filings with the Securities and Exchange Commission for a detailed discussion of potential risks. Based on current InvestingPro analysis, the stock appears slightly overvalued, though analysts maintain a bullish outlook with 7 recent upward earnings revisions. Discover more insights and 12 additional ProTips with an InvestingPro subscription, including access to comprehensive Pro Research Reports covering 1,400+ top US stocks.
The information regarding the dividend is based on the company’s recent press release statement. Eli Lilly emphasizes its dedication to innovation in clinical trials and the accessibility and affordability of its medicines. It aims to ensure that its treatments reflect the diversity of the global population and meet a broad range of medical needs.
Investors and the media can find additional information about Eli Lilly’s initiatives and financial strategies on the company’s website and official news channels.
In other recent news, Eli Lilly reported its first-quarter 2025 results, showing a substantial 45% increase in revenue compared to the same period last year, driven by strong sales of key products. However, the company missed its earnings per share forecast, reporting $3.34 against an expected $3.46, which contributed to a negative market reaction. In light of this, Eli Lilly adjusted its full-year earnings forecast to a range of $20.78 to $22.28 per share, below the anticipated $22.40, while maintaining its revenue projection at $58-61 billion. Meanwhile, CVS Caremark announced a partnership with Novo Nordisk, making Wegovy the preferred GLP-1 drug for obesity, which has affected Eli Lilly’s market position as CVS will favor Wegovy over Eli Lilly’s Zepbound. This development has raised concerns about pricing power within the GLP-1 drug class. Analyst firms have responded differently to these events; UBS reduced its price target for Eli Lilly to $1,050 but maintained a Buy rating, while Cantor Fitzgerald kept a $975 target with an Overweight rating, expressing confidence in the company’s market position. Leerink Partners maintained an Outperform rating with a $944 target, viewing the stock dip as a buying opportunity, citing a stable long-term outlook for Eli Lilly’s revenue and earnings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.